Subsurface profiling of granite pluton using microtremor method: southern Aravalli, Gujarat, India

We report, using the microtremor method, a subsurface granitic pluton underneath the Narukot Dome and in its western extension along a WNW profile, in proximity of eastern fringe of Cambay Rift, India. The dome and its extension is a part of the Champaner Group of rocks belonging to the Mesoproterozoic Aravalli Supergroup. The present finding elucidates development of an asymmetric double plunge along Narukot Dome. Microtremor measurements at 32 sites were carried out along the axial trace (N95°) of the dome. Fourier amplitude spectral studies were applied to obtain the ratio between the horizontal and vertical components of persisting Rayleigh waves as local ambient noise. Fundamental resonant frequencies with amplitude ≥1-sigma for each site are considered to distinguish rheological boundary. Two distinct rheological boundaries are identified based on frequency ranges determined in the terrain: (1) 0.2219–10.364 Hz recorded at 31 stations identified as the Champaner metasediment and granite boundary, and (2) 10.902–27.1119 Hz recorded at 22 stations identified as the phyllite and quartzite boundary. The proposed equation describing frequency–depth relationship between granite and overlaying regolith matches with those already published in the literature. The morphology of granite pluton highlights the rootless character of Champaner Group showing sharp discordance with granitic pluton. The findings of manifestation of pluton at a shallower depth imply a steep easterly plunge within the Champaner metasediments, whereas signature of pluton at a deeper level implies a gentle westerly plunge. The present method enables to assess how granite emplacement influences the surface structure

Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)

BACKGROUND: Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control. METHODS: Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15-99 years) and 75,000 children (age 0-14 years) diagnosed with cancer during 1995-2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. FINDINGS: 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005-09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15-19% in North America, and as low as 7-9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10-20% between 1995-99 and 2005-09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995-99 and 2005-09 have generally been slight. For women diagnosed with ovarian cancer in 2005-09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005-09 was high (54-58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18-23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major deficiencies in the management of a largely curable disease. INTERPRETATION: International comparison of survival trends reveals very wide differences that are likely to be attributable to differences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems